Nephrology Journal Club Profile picture
Dec 9, 2022 10 tweets 5 min read Read on X
Would a new drug option for resistant hypertension get you excited? How about a superior trial design?

Time to learn about PRECISION - our twitter journal club had 720 tweets, but you can catch the highlights quickly with the regular #TenTweetNephJC thread👇 Image
2/10
What did I miss?

We know we miss targeting many pathways that contribute to resistant hypertension, a condition with high cardiovascular morbidity.

Enter aprocitentan, a dual endothelin receptor antagonist, for it’s crack at a Phase 3 trial.

pubmed.ncbi.nlm.nih.gov/36356632/
3/10
1 tweet methods

✅ Multi-center, blinded, randomised, parallel-group

✅ Elaborate run-in (figure) to give all amlod + HCTZ + valsartan, and then exclude pseudoresistant hypertension

✅ Does adding aprocitentan to regime improve unattended automated office BP 🆚 placebo? Image
4/10
1 tweet results

🔹730 patients randomised

🔹Mean age 62, 63% on ≥4 antihypertensives, baseline office BP 153/88

🔹At 4 weeks = reduction of 15.3mmHg systolic for aprocitentan, versus 11.5mmHg reduction with placebo
5/10
A figure paints 1000 words

Also had proof of efficacy in ambulatory BP monitoring Image
6/10
Give me something clever to say

“The Achilles heel of endothelin receptor antagonists has been fluid retention & PRECISION followed suit, with uncomfortable rates of heart failure in the aprocitentan arm. Might co-prescription with a flozin mitigate these adverse events?”
7/10
Chat consensus?

1️⃣ Aprocitentan does work in resistant hypertension, proven by convincing trial design

2️⃣ uACR 30% reduction encouraging

3️⃣ BUT this was a trial against placebo, not spiro that we actually use 4th line, is cardioprotective, is inexpensive, is beloved
8/10
Quote of the fortnight!

I think everyone agrees with @goupil_remi - an antihypertensive as good as doxazosin is worth limited celebration…

9/10
I want more info

✅ Is it reasonable to expect proof of end organ benefit in resistant hypertension trials? Enjoy working through the sums in this fantastic thread by @ProfDFrancis


✅ Summary @thana_susan
nephjc.com/news/aprociten…

✅ VA @Sandyrvsdav Image
10/10
Final thoughts

✳️ For now, we’ll stick with spiro & flozins

➡️ Coming 20/21 Dec - Lancet again for MyTEMP, the largest ever trial in patients on haemodialysis, looking at CV outcomes with standard 🆚 cooled dialysate
pubmed.ncbi.nlm.nih.gov/36343653/

Tweetorial by @jamiekwillows

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Nephrology Journal Club

Nephrology Journal Club Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @NephJC

Jun 7, 2023
Welcome to #TenTweetNephJC
✳️10 tweets #NephJC catch-up ✳️

In the last NephJC, we discussed interim results📊from the PROTECT trial on efficacy & safety of Sparsentan in IgAN.

New light✨on the horizon for IgAN yet?

Check out this flying summary in case you've missed the chat! Image
2/10
What did I miss?

3 decades of fateful trials of ERAs in PAH, HTN, DKD, FSGS & IgAN (AFFINITY,ALIGN) set the stage for

🛡️PROTECT🛡️
Sparsentan🎲Irbesartan
thelancet.com/journals/lance…

✔️Phase3⃣RCT
✔️Active-controlled
✔️Double-blind🚫

✔️18 countries🗺️
✔️134 sites🏥

The cohort⬇️ Image
3/10
1 tweet methods

n=406
270 weeks (114+156 weeks open label with SGLT2i!)

➡️Carefully selected population for nil significant cardio/cerebro-vascular or hepatic disease
➡️On MLD/50% MLD of RAASi
➡️1:1 randomisation
➡️Stratification as per eGFR & proteinuria
➡️MMRM statistics Image
Read 11 tweets
Apr 5, 2023
Welcome to #TenTweetNephJC for a short recap! Nephrologists warned of renalism neglecting cardiac ischemia in kidney pts. ISCHEMIA-CKD dashed hopes. Waiting for a deceased donor kidney transplant in the US is a grueling journey for +100K pts with advanced chronic kidney disease Image
2/10
What did I miss?
🌤️Retrospective study: asymptomatic kidney transplant candidates tested for coronary heart disease (CHD) vs non-tested pubmed.ncbi.nlm.nih.gov/36595271/
Aim: to determine the effect of CHD testing on the risk of death or acute MI within 30 days after transplant
3/10
1 tweet methods

⏪ Retrospective cohort study, USRDS, 2000-2014

✅ 79334 Adults, 1st time kidney transplant

✅ CHD testing 12 months before transplant

🛠️ Instrumental analysis variable - less biased by confounding than standard methods @Husamjz ImageImage
Read 11 tweets
Dec 20, 2022
#1
A few hours to go for the #NephJC chat on the MYTEMP trial ⏳

❓Have you ever paused to wonder how we came up with the ‘standard’ dialysate temperature of 37°C (98.6°F)???🤔

❓How does core body temperature (CBT) differ in dialysis patients from the general population?🤔
#2
👉Historical reasons for std dialysate 🌡️seem unclear

👉37°C considered avg body 🌡️in adults ⏩ arbitrarily selected as ‘neutral’ dialysate 🌡️

👉Assumed to prevent body 🌡️ changes during HD

#NephJC

pubmed.ncbi.nlm.nih.gov/15211448/
#3
❓How did we come up with 37°C as the normal body 🌡️?

👉From Dr. Carl Wunderlich
▶️Father of clinical thermometry
▶️Analyzed >1million axillary 🌡️from 25K adults (pre-digital era!🤯)
▶️Noted 🌡️differences with race, sex, circadian rhythm
#NephJC
pubmed.ncbi.nlm.nih.gov/8011836/
Read 7 tweets
Apr 8, 2022
✳️ #TenTweetNephJC ✳️

👉 where we catch you up on the week's #NephJC chat in 10 tweets 

The topic at hand was Plasma Exchange and Vasculitis: the infamous debate of to PLEX or not to PLEX in AAV

Check out this thread to see if you change your mind on this comPLEX topic 👇 Image
What did I miss?

PLEX, with its plausible biological rationale, has been in the center of debate for management of AAV since the 1980s, with several RCTs in favor of PLEX or against it

🔸️An updated meta-analysis which included the PEXIVAS results was discussed
1 tweet methods

✅ updated systematic review & meta-analysis

✅ RCTs of patients with AAV or pauci-immune RPGN receiving PLEX and ≥12mo. follow-up

✅ Outcome measures were at least one of: mortality, ESKD, serious infection, relapse, AE or health-related QoL
Read 10 tweets
Mar 25, 2022
✳️ Welcome to #TenTweetNephJC, where we catch you up on the week's #NephJC chat in 10 tweets ✳️

The topic at hand was diuretic resistance, specifically compensatory post-diuretic sodium reabsorption (CPDSR). Let’s walk you through how it all flowed 💧
What did I miss?

We teach medical students that diuretic resistance occurs in large part due to CPDSR. While this has been validated in healthy individuals, does this hold true in patients w/ acute decomp heart failure (ADHF)?
Enter the study in question
pubmed.ncbi.nlm.nih.gov/34529781/
1 tweet methods

✅Single center, prospective, observational study, with a randomized sub-cohort
✅Evaluating mechanisms of diuretic resistance in patients with ADHF on IV loops 💉
✅Supervised urine collection pre and post diuresis
✅Primary outcome = level of CPDSR
Read 10 tweets
Mar 13, 2022
This weeks #TenTweetNephJC makes us sad - does taking regular acetaminophen (paracetamol) cause hypertension?

Find out below in this rapid review of the Scottish trial, as we catch up on the #NephJC take on things 👇 Image
What did I miss?

Observational trials suggest that acetaminophen increases BP, but (unlike NSAIDs) the widespread impression remains of a safe first-line therapy for chronic pain. The largest previous RCT had n=33.

Then PATH-BP dropped last month….

pubmed.ncbi.nlm.nih.gov/35130054/
1 Tweet Methods

✔️ Single-centre, double-blind, placebo-controlled, crossover study

✔️ 4g/day acetaminophen (the standard UK dose) 🆚 placebo

✔️ 2 weeks active or placebo ➡️ 2 weeks washout ➡️ 2 weeks on opposite treatment

✔️ Primary outcome = change in 24 hour ambulatory BP
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(